The BRAF inhibitor AMB-1310 is currently being studied in both the United States and China for the treatment of patients with glioblastoma who are carrying the BRAF V600E mutation.
/PRNewswire/ ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the.
/PRNewswire/ Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term.